PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of springeropenLink to Publisher's site
The International Journal of Cardiovascular Imaging
 
Int J Cardiovasc Imaging. 2010 August; 26(6): 661–664.
Published online 2010 April 1. doi:  10.1007/s10554-010-9612-5
PMCID: PMC2898113

Positron emission tomography; viable tool in patients pre-CABG?

Assessment of myocardial viability and ischemia continues to be an important issue in patients with coronary artery disease and left ventricular dysfunction [110]. In particular in patients following a myocardial infarction and in the evaluation of patients eligible for interventional procedures such as coronary artery bypass grafting (CABG), accurate assessment of myocardial viability remains pivotal [1114]. To assess myocardial viability, different diagnostic methods are currently performed, such as FDG/PET, MRI, SPECT, and echocardiography [1528]. In the clinical arena, detection of myocardial viability is predominantly based on the use of nuclear techniques, which show preserved tracer uptake and metabolism in viable myocardium. FDG/PET is considered the reference standard due to its ability to differentiate dysfunctional but viable myocardium from scar formation and normal myocardium [2938]. In patients with ischemic cardiomyopathy, CABG offers an important therapeutic option but this operative procedure is still associated with a high perioperative mortality. Although previous studies suggest a benefit from revascularization for patients with defined viability by a non-invasive technique [3944], the role of viability assessment to determine suitability for revascularization in patients with ischemic cardiomyopathy has not yet been defined.

In the current issue of the International Journal of Cardiovascular Imaging, Boehm et al. [45] evaluated the hypothesis that the use of PET imaging in the decision-making process for CABG will improve postoperative patient survival. The authors studied 476 patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) who were considered candidates for CABG. In a Standard Care Group, 298 patients underwent CABG. In a second PET-guided management group (n-178), 152 patients underwent PET-CABG; 26 patients were excluded from CABG because of lack of viability. The survival rate after 1, 5 and 9.3 years was 92.0, 73.3 and 54.2% in the PET-CABG group and 88.9, 62.2 and 35.5% in the Standard Care Group, respectively (P = 0.005). There was a statistically significant influence on long-term survival using FDG-PET data, left ventricular function, and age over 70 years. Consequently, preoperative assessment of myocardial viability trough FDG-PET imaging identified patients who will benefit most from CABG.

The crucial finding of the present study was the significant reduction of the 30-day mortality in the PET-CABG group with 1.3 vs. 10.3% in the Standard Care group. The observed early mortality rate of 1.3% in the PET-CABG group is lower than observed in the STICH trial (Surgical Treatment for Ischemic Heart Failure) that reported a hospital mortality of 5% [46]. The early survival benefit of the PET-CABG group persisted in the long-term as reflected by the superior survival of the PET-CABG over a 10 year follow-up. Another important message of the present study was that he criterion of scar extent alone was not sufficient for the selection process. Four patients in the PET-CABG group showed a scar tissue area ≥40%. However, in these patients the other main viability criteria and the angiographic report supported the decision that these patients were adequate candidates for CABG.

The concept of a preoperative PET-based selection of patients who benefit mostly from CABG was examined by Haas et al. [47] who found a significant reduction in perioperative mortality in patient with defined viability. In the PARR-2 study (positron emission tomography and recovery following revascularization), patients with ischemic cardiomyopathy were randomized to management guided by FDG-PET (n = 218) or standard care (n = 212) [48]. In a subgroup of patients who adhered to PET recommendations regarding revascularization, significant survival benefits were observed. These findings are supported by the present study of Boehm et al. [45] in which every patient with sufficient viability in the PET-assisted group underwent CABG and showed significantly improved mortality rates after revascularization.

The current study did not compare FDG-PET with other imaging modalities for detection of viable myocardium such as gated SPECT imaging, MRI or low dose dobutamine echocardiography, which may have provided additional important information in the decision process for CABG. To that purpose, Siebelink et al. [49] sought to prospectively compare nitrogen-13 (13 N)-ammonia/18FDG-PET guided management with stress/rest 99mTc-sestamibi SPECT-guided management in 103 patients considered for revascularization with left ventricular wall motion abnormalities and suspicion of jeopardized myocardium. In terms of cardiac event-free survival, no differences between PET and SPECT were observed (11 vs. 13 cardiac events for PET and SPECT, respectively). No differences in patient management or cardiac event-free survival were demonstrated between management based on 13 N-ammonia/18FDG PET and that based on stress/rest 99mTc-sestamibi SPECT imaging. Both techniques may be used for viability-guided management of patients considered for revascularization with suspicion of jeopardized myocardium.

To summarize, the study by Boehm et al. [45] reemphasizes the need for accurate preoperative viability imaging in patients with ischemic cardiomyopathy. Viability guided assessment may result in a significant reduction of peri-operative mortality rates after CABG. However, the question of viability assessment to determine suitability for revascularization is still not fully resolved and an optimal diagnostic protocol in patients with ischemic cardiomyopathy has to be defined. Consequently, larger studies are necessary to further evaluate the impact of preoperative viability assessment in this high-risk group of patients.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Footnotes

Editorial Comment on the article Boehm et al. (doi: 10.1007/s10554-010-9585-4).

References

1. Bax JJ, Lamb H, Dibbets P, Pelikan H, et al. Comparison of gated single-photon emission computed tomography with magnetic resonance imaging for evaluation of left ventricular function in ischemic cardiomyopathy. Am J Cardiol. 2000;86:1299–1305. doi: 10.1016/S0002-9149(00)01231-5. [PubMed] [Cross Ref]
2. Bax JJ, Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart. 2004;90(Suppl 5):v26–33. doi: 10.1136/hrt.2002.007575. [PMC free article] [PubMed] [Cross Ref]
3. Wall EE, Heidendal GA, Hollander W, Westera G, Roos JP. I-123 labeled hexadecenoic acid in comparison with Thallium-201 for myocardial imaging in coronary heart disease. A preliminary study. Eur J Nucl Med. 1980;5:401–405. doi: 10.1007/BF00261781. [PubMed] [Cross Ref]
4. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653 [PubMed]
5. Slart RH, Bax JJ, Sluiter WJ, Veldhuisen DJ, Jager PL. Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: comparison with FDG SPECT. J Nucl Cardiol. 2004;11:689–696. doi: 10.1016/j.nuclcard.2004.06.131. [PubMed] [Cross Ref]
6. Bavelaar-Croon CD, Pauwels EK, Wall EE. Gated single-photon emission computed tomographic myocardial imaging: a new tool in clinical cardiology. Am Heart J. 2001;14:383–390. doi: 10.1067/mhj.2001.112780. [PubMed] [Cross Ref]
7. Bavelaar-Croon CD, Kayser HW, Wall EE, et al. Left ventricular function: correlation of quantitative gated SPECT and MR imaging over a wide range of values. Radiology. 2000;217:572–575. [PubMed]
8. Sciagrà R, Leoncini M. Gated single-photon emission computed tomography. The present-day ‘‘one-stop-shop’’ for cardiac imaging. Q J Nucl Med Mol Imaging. 2005;49:19–29. [PubMed]
9. America YG, Bax JJ, Dibbets-Schneider P, Pauwels EK, Wall EE. Evaluation of the Quantitative Gated SPECT (QGS) software program in the presence of large perfusion defects. Int J Cardiovasc Imaging. 2005;21:519–529. doi: 10.1007/s10554-005-0274-7. [PubMed] [Cross Ref]
10. Eck-Smit BL, Wall EE, Kuijper AF, Zwinderman AH, Pauwels EK. Immediate thallium-201 reinjection following stress imaging: a time-saving approach for detection of myocardial viability. J Nucl Med. 1993;34:737–743. [PubMed]
11. Groutars RG, Verzijlbergen JF, Tiel-van Buul MM, et al. The accuracy of 1-day dual-isotope myocardial SPECT in a population with high prevalence of coronary artery disease. Int J Cardiovasc Imaging. 2003;19:229–238. doi: 10.1023/A:1023637804898. [PubMed] [Cross Ref]
12. Wall EE, Hollander W, Heidendal GA, Westera G, Majid PA, Roos JP. Dynamic myocardial scintigraphy with 123I-labeled free fatty acids in patients with myocardial infarction. Eur J Nucl Med. 1981;6:383–389. [PubMed]
13. Hoeven BL, Pires NM, Warda HM, et al. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005;99:9–17. doi: 10.1016/j.ijcard.2004.01.021. [PubMed] [Cross Ref]
14. Langerak SE, Vliegen HW, Roos A, et al. Detection of vein graft disease using high-resolution magnetic resonance angiography. Circulation. 2002;105:328–333. doi: 10.1161/hc0302.102598. [PubMed] [Cross Ref]
15. Wall EE, Dijkman PR, Roos A, et al. Diagnostic significance of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in thrombolytic treatment for acute myocardial infarction: its potential in assessing reperfusion. Br Heart J. 1990;63:12–17. doi: 10.1136/hrt.63.1.12. [PMC free article] [PubMed] [Cross Ref]
16. Dijkman PR, Wall EE, Roos A, et al. Acute, subacute, and chronic myocardial infarction: quantitative analysis of gadolinium-enhanced MR images. Radiology. 1991;180:147–151. [PubMed]
17. Roos A, Matheijssen NA, Doornbos J, Dijkman PR, Voorthuisen AE, Wall EE. Myocardial infarct size after reperfusion therapy: assessment with Gd-DTPA-enhanced MR imaging. Radiology. 1990;176:517–521. [PubMed]
18. Roos A, Matheijssen NA, Doornbos J, Dijkman PR, Rugge PR, Wall EE. Myocardial infarct sizing and assessment of reperfusion by magnetic resonance imaging: a review. Int J Card Imaging. 1991;7:133–138. doi: 10.1007/BF01798054. [PubMed] [Cross Ref]
19. Vliegen HW, Doornbos J, Roos A, Jukema JW, Bekedam MA, Wall EE. Value of fast gradient echo magnetic resonance angiography as an adjunct to coronary arteriography in detecting and confirming the course of clinically significant coronary artery anomalies. Am J Cardiol. 1997;79:773–776. doi: 10.1016/S0002-9149(96)00866-1. [PubMed] [Cross Ref]
20. Hoogendoorn LI, Pattynama PM, Buis B, Geest RJ, Wall EE, Roos A. Noninvasive evaluation of aortocoronary bypass grafts with magnetic resonance flow mapping. Am J Cardiol. 1995;75:845–848. doi: 10.1016/S0002-9149(99)80429-9. [PubMed] [Cross Ref]
21. Rugge FP, Holman ER, Wall EE, Roos A, Laarse A, Bruschke AV. Quantitation of global and regional left ventricular function by cine magnetic resonance imaging during dobutamine stress in normal human subjects. Eur Heart J. 1993;14:456–463. [PubMed]
22. Geest RJ, Roos A, Wall EE, Reiber JH. Quantitative analysis of cardiovascular MR images. Int J Card Imaging. 1997;13:247–258. doi: 10.1023/A:1005869509149. [PubMed] [Cross Ref]
23. Geest RJ, Niezen RA, Wall EE, Roos A, Reiber JH. Automated measurement of volume flow in the ascending aorta using MR velocity maps: evaluation of inter- and intraobserver variability in healthy volunteers. J Comput Assist Tomogr. 1998;22:904–911. doi: 10.1097/00004728-199811000-00013. [PubMed] [Cross Ref]
24. Rugge FP, Wall EE, Dijkman PR, Louwerenburg HW, Roos A, Bruschke AV. Usefulness of ultrafast magnetic resonance imaging in healed myocardial infarction. Am J Cardiol. 1992;70:1233–1237. doi: 10.1016/0002-9149(92)90754-M. [PubMed] [Cross Ref]
25. Holman ER, Jonbergen HP, Dijkman PR, Laarse A, Roos A, Wall EE. Comparison of magnetic resonance imaging studies with enzymatic indexes of myocardial necrosis for quantification of myocardial infarct size. Am J Cardiol. 1993;71:1036–1040. doi: 10.1016/0002-9149(93)90569-X. [PubMed] [Cross Ref]
26. Bleeker GB, Schalij MJ, Holman ER, Steendijk P, Wall EE, Bax JJ. Cardiac resynchronization therapy in patients with systolic left ventricular dysfunction and symptoms of mild heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2006;98:230–235. doi: 10.1016/j.amjcard.2006.01.080. [PubMed] [Cross Ref]
27. Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97:260–263. doi: 10.1016/j.amjcard.2005.08.030. [PubMed] [Cross Ref]
28. Tulevski II, Hirsch A, Sanson BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 2001;86:1193–1196. [PubMed]
29. Pluim BM, Lamb HJ, Kayser HW, Leujes F, et al. Functional and metabolic evaluation of the athlete’s heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation. 1998;97:666–672. [PubMed]
30. Pluim BM, Beyerbacht HP, Chin JC, et al. Comparison of echocardiography with magnetic resonance imaging in the assessment of the athlete’s heart. Eur Heart J. 1997;18:1505–1513. [PubMed]
31. Pluim BM, Chin JC, Roos A, et al. Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance imaging and spectroscopy. Eur Heart J. 1996;17:1271–1278. [PubMed]
32. Braun S, Wall EE, Emanuelsson S, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40–5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The mibefradil international study group. J Am Coll Cardiol. 1996;27:317–322. doi: 10.1016/0735-1097(95)00472-6. [PubMed] [Cross Ref]
33. Portegies MC, Schmitt R, Kraaij CJ, et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40–5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol. 1991;18:746–751. doi: 10.1097/00005344-199111000-00013. [PubMed] [Cross Ref]
34. Nooijer R, Verkleij CJ, der Thüsen JH, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340–346. doi: 10.1161/01.ATV.0000197795.56960.64. [PubMed] [Cross Ref]
35. Laarse A, Kerkhof PL, Vermeer F, et al. Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am J Cardiol. 1988;61:1–7. doi: 10.1016/0002-9149(88)91294-5. [PubMed] [Cross Ref]
36. Bakx AL, Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40–5967 International Study Group. Am Heart J. 1995;130:748–757. doi: 10.1016/0002-8703(95)90073-X. [PubMed] [Cross Ref]
37. Rugge FP, Boreel JJ, Wall EE, et al. Cardiac first-pass and myocardial perfusion in normal subjects assessed by sub-second Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:959–965. doi: 10.1097/00004728-199111000-00010. [PubMed] [Cross Ref]
38. Nijveldt R, Beek AM, Hirsch A, et al. ‘No-reflow’ after acute myocardial infarction: direct visualisation of microvascular obstruction by gadolinium-enhanced CMR. Neth Heart J. 2008;16:179–181. [PMC free article] [PubMed]
39. Bax JJ, Visser FC, Lingen A, Cornel JH, Fioretti PM, Wall EE. Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. Int J Card Imaging. 1997;13:145–155. doi: 10.1023/A:1005744810876. [PubMed] [Cross Ref]
40. Underwood SR, Bax JJ, vom Dahl J, et al. Study Group of the European Society of Cardiology. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J. 2004;25:815–836. doi: 10.1016/j.ehj.2004.03.012. [PubMed] [Cross Ref]
41. Slart RH, Bax JJ, Boer J, et al. Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. Eur J Nucl Med Mol Imaging. 2005;32:972–979. doi: 10.1007/s00259-005-1785-0. [PubMed] [Cross Ref]
42. Slart RH, Bax JJ, Veldhuisen DJ, Wall EE, Dierckx RA, Jager PL. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int J Cardiovasc Imaging. 2006;22:63–80. doi: 10.1007/s10554-005-7514-8. [PubMed] [Cross Ref]
43. Slart RH, Bax JJ, Veldhuisen DJ, et al. Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13 N-ammonia/18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:716–723. doi: 10.1007/s00259-005-0016-z. [PubMed] [Cross Ref]
44. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med. 2009;50:214–219. doi: 10.2967/jnumed.108.054395. [PubMed] [Cross Ref]
45. Boehm J, Haas F, Bauernschmitt R et al (2010) Impact of preoperative positron emission tomography in patients with severely impaired LV-function undergoing surgical revascularization. Int J Cardiovasc Imaging [Epub ahead of print] [PMC free article] [PubMed]
46. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693–1700. doi: 10.1016/S0735-1097(97)00375-6. [PubMed] [Cross Ref]
47. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–1717. doi: 10.1056/NEJMoa0900559. [PMC free article] [PubMed] [Cross Ref]
48. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2) J Am Coll Cardiol. 2007;50:2002–2012. doi: 10.1016/j.jacc.2007.09.006. [PubMed] [Cross Ref]
49. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37:81–88. doi: 10.1016/S0735-1097(00)01087-1. [PubMed] [Cross Ref]

Articles from Springer Open Choice are provided here courtesy of Springer